Rankings · Quality
A+ companies
Graded A on the five growth-and-cash checks and strong on business quality — margins, returns and debt — which is what the plus means. Ranked by size.
32 companies meet this test
Figures as of November 15, 2026
| # | Company | Grade | Market value | Net margin | Return on capital | Revenue growth |
|---|---|---|---|---|---|---|
| 1 | LLYELI LILLY AND COMPANY | A+ | $1.36T | 31.9% | — | +39% a year |
| 2 | JNJJohnson & Johnson | A+ | $687.9B | 16.2% | 12.0% | +6% a year |
| 3 | TMOTHERMO FISHER SCIENTIFIC INC. | A+ | $259.4B | 14.9% | 7.6% | +3% a year |
| 4 | AMGNAmgen Inc. | A+ | $251.9B | 24.1% | 12.5% | +13% a year |
| 5 | ISRGIntuitive Surgical, Inc. | A+ | $153.8B | 25.5% | 14.3% | +19% a year |
| 6 | MDTMedtronic plc | A+ | $131.6B | 13.9% | 6.6% | +6% a year |
| 7 | SYKSTRYKER CORP | A+ | $117.9B | 13.8% | 9.3% | +10% a year |
| 8 | GSKGSK plc | A+ | $108.9B | 17.5% | 19.0% | +4% a year |
| 9 | EWEDWARDS LIFESCIENCES CORPORATION | A+ | $61.6B | 15.3% | 9.4% | +17% a year |
| 10 | IDXXIDEXX LABORATORIES INC /DE | A+ | $55.5B | 25.4% | 50.9% | +9% a year |
| 11 | VEEVVeeva Systems Inc. | A+ | $48.8B | 29.3% | 9.8% | — |
| 12 | ONCBEONE MEDICINES LTD. | A+ | $47.6B | 13.9% | 7.2% | +44% a year |
| 13 | ILMNIllumina, Inc. | A+ | $31.3B | 19.7% | 13.4% | +1% a year |
| 14 | THCTENET HEALTHCARE CORP | A+ | $22.8B | 17.2% | 16.5% | +3% a year |
| 15 | NBIXNEUROCRINE BIOSCIENCES, INC. | A+ | $16.9B | 19.0% | 12.5% | +28% a year |
| 16 | EXELEXELIXIS, INC. | A+ | $16.8B | 35.5% | 31.3% | +12% a year |
| 17 | EHCEncompass Health Corporation | A+ | $13.8B | 10.2% | 7.6% | +11% a year |
| 18 | TECHBIO-TECHNE Corp | A+ | $11.4B | 14.0% | 7.8% | +2% a year |
| 19 | HALOHALOZYME THERAPEUTICS, INC. | A+ | $11.4B | 26.9% | 16.1% | +32% a year |
| 20 | TGTXTG THERAPEUTICS, INC. | A+ | $9.8B | 11.8% | 10.8% | — |
| 21 | HNGEHinge Health, Inc. | A+ | $9.4B | 21.0% | -290.9% | +40% a year |
| 22 | KRYSKrystal Biotech, Inc. | A+ | $9B | 47.9% | 10.4% | — |
| 23 | HQYHEALTHEQUITY, INC. | A+ | $8.6B | 17.4% | 8.2% | +13% a year |
| 24 | PTGXPROTAGONIST THERAPEUTICS, INC. | A+ | $8.5B | 62.0% | -25.2% | — |
| 25 | KNSAKiniksa Pharmaceuticals International, plc | A+ | $8.2B | 11.6% | 10.5% | — |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.